Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …

Background Low‐molecular‐weight‐heparins (LMWHs) have been established for the
treatment of cancer‐associated venous thromboembolism (VTE). Recently published …

Efficacy and safety of anticoagulant treatment for venous thromboembolism (VTE) may vary
in patients with different cancer sites. We evaluated the rates of VTE recurrence and major …

Patients with cancer are prone to develop venous thromboembolism (VTE) that is the
second leading cause of mortality among them. Cancer patients with VTE may encounter …

Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism
(VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the …

Background Patients with cancer-associated venous thromboembolism (VTE) have a high
risk of VTE recurrence and anticoagulant treatment–related bleeding, but the correlation of …

Venous thromboembolism (VTE) is a common complication in patients with cancer. The risk
of emergent VTE is four-to seven-fold higher in cancer patients compared to non-cancer …

Abstract Background Direct oral anticoagulants (DOACs) are recommended for stroke
prevention in patients with atrial fibrillation (AF) or for treatment of deep vein thrombosis …

Venous thromboembolism (VTE) is often associated with malignant diseases and notably
contributes to morbidity and mortality in patients with cancer. Cancer‐associated thrombosis …

Background Patients with acute venous thromboembolism associated with cancer have an
increased risk of recurrences and bleeding in the long term. Research question To describe …